MET and neoplasm: In this study, we chose a novel, peptide-based molecular imaging agent with 18F-tracer, which binds to human c-Met with high affinity, has a favorable kinetic profile, exhibits specific uptake in c-Met positive H&N tumor mouse model, and rapid renal clearance.